Real-World asthma drug study shows Life-Improving potential
NCT ID NCT06018441
Summary
This study followed 112 adults with severe, hard-to-control asthma who were starting treatment with the drug dupilumab (brand name Dupixent®). The main goal was to see if their quality of life improved over one year of treatment in a real-world setting, outside of a tightly controlled clinical trial. Researchers tracked changes in symptoms, daily activity, and overall well-being, while also monitoring for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
France, France
Conditions
Explore the condition pages connected to this study.